Establishment Labs Holdings Inc. (NASDAQ:ESTA) Short Interest Update

Establishment Labs Holdings Inc. (NASDAQ:ESTA) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 4,930,000 shares, a growth of 8.1% from the March 15th total of 4,560,000 shares. Based on an average daily trading volume, of 457,400 shares, the short-interest ratio is presently 10.8 days. Approximately 21.7% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Stephens restated an “overweight” rating and set a $47.00 price objective on shares of Establishment Labs in a report on Thursday, January 11th. JPMorgan Chase & Co. lifted their target price on shares of Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Mizuho lifted their target price on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Finally, Citigroup lifted their target price on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Establishment Labs presently has an average rating of “Buy” and a consensus price target of $63.33.

Hedge Funds Weigh In On Establishment Labs

Large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its position in Establishment Labs by 3,244.4% during the first quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock valued at $41,000 after purchasing an additional 584 shares during the last quarter. Baker Avenue Asset Management LP bought a new stake in Establishment Labs during the third quarter valued at approximately $59,000. Global Retirement Partners LLC bought a new stake in Establishment Labs during the third quarter valued at approximately $60,000. Lazard Asset Management LLC lifted its position in Establishment Labs by 104.5% during the first quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock valued at $64,000 after purchasing an additional 492 shares during the last quarter. Finally, Deutsche Bank AG bought a new stake in Establishment Labs during the fourth quarter valued at approximately $66,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Price Performance

Shares of ESTA stock traded up $0.41 during trading hours on Wednesday, reaching $52.15. The stock had a trading volume of 202,493 shares, compared to its average volume of 435,597. The stock’s fifty day simple moving average is $46.09 and its 200 day simple moving average is $36.07. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $77.55. The firm has a market capitalization of $1.43 billion, a PE ratio of -17.35 and a beta of 1.24.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The company had revenue of $31.60 million during the quarter, compared to analyst estimates of $31.44 million. During the same period last year, the business earned ($0.55) earnings per share. Establishment Labs’s revenue was down 27.9% compared to the same quarter last year. On average, equities research analysts predict that Establishment Labs will post -1.58 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.